Search

Search Constraints

You searched for: Author/Creator Fong, Peter C

Search Results

1. 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. (20th October 2022)

2. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Issue 3 (March 2015)

3. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Issue 3 (March 2015)

4. Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer. (February 2014)

5. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Issue 5 (May 2020)

6. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 10106 (28th October 2017)

7. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Issue 7 (8th June 2021)

8. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression‐free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. Issue 7 (July 2021)

9. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study. Issue 6 (June 2015)